Global Biopharmaceutical Excipient Manufacturing Market

Report ID : 1197 | Published : 2022-02-01 | Pages: | Format:

Excipients are carrier agents beneficial for biopharmaceutical formulations. They offer efficient binding of ingredients, increase drug stability in the dosage form and modify the solubility of API. Excipients are inert, reproducible substances created from minerals, sugar, wheat, corn, and other such ingredients. They can reduce operating costs, enhance productivity, and improve product quality. The Global Biopharmaceutical Excipient Manufacturing Market is valued at US$ 1156.5 Mn in 2021, and it is expected to reach US$ 2624.3 Mn by 2030, with a CAGR of 9.7 % during a forecast period of 2022-2030.

Major driving factors of the biopharmaceutical excipient manufacturing market are the surging applications of excipients, increasing initiatives by market players to develop excipients for innovating high-quality drugs, growing focus on the development of novel drugs, rising cases of chronic diseases, increasing use of lipid and sucrose-based excipients, advances in the field of pharmaceutical manufacturing, and the increasing R&D activities in the pharmaceutical industries. The increasing COVID cases have increased the drug manufacturing burden of biopharmaceutical companies to treat the affected patients. Hence, companies are rising their focus on fast drug development. Excipients are effective and efficient in enhancing the manufacturing process for biopharmaceuticals. Therefore, the demand for biopharmaceutical excipients is surging to develop innovative and stabilized drugs, thereby creating significant growth opportunities during the forecast period. However, complexities associated with drug manufacturing along with the requirement of high capital investments may hinder the market growth during the forecast period.

The biopharmaceutical excipient manufacturing market is segmented based on the type of biologics, excipient types, scale of operation, and region. The type of biologics segment comprises antibodies, vaccines, cell therapies, and other biologics. The market is categorized into carbohydrates, polymers, solubilizers/surfactants, polyols, proteins/amino acids, and others in terms of excipient types. The carbohydrates segment is expected to dominate this market in the forthcoming years due to the rising use of carbohydrate-based excipient products such as sucrose and starch in drug formulations. By scale of operation, the market is classified into preclinical, clinical, and commercial. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Asia-Pacific is estimated to be the rapidly growing regional market in the next few years due to the increasing incidences of chronic diseases, rising government funding for healthcare, and the growing demand for drugs. India and China are the emerging countries of this market

Some of the key players operating in the biopharmaceutical excipient manufacturing market are ABITEC (US), Avantor (US), BASF Pharma (Germany), Corden Pharma (Germany), DFE Pharma (Germany), Evonik (Germany), Kirsch Pharma (Germany), Merck KGaA (Germany), Pfanstiehl (US), Roquette (France), Spectrum Chemical Manufacturing (US), SPI Pharma (US), and Others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biopharmaceutical Excipient Manufacturing Market Snapshot

Chapter 4. Global Biopharmaceutical Excipient Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Route of Administration, Estimates & Trend Analysis

5.1. By Biologics Types, & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Biologics Types:

5.2.1. Antibodies

5.2.2. Vaccines

5.2.3. Cell Therapies

5.2.4. Other Biologics

Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis

6.1. By Excipient & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Excipient:

6.2.1. Carbohydrates

6.2.2. Polymers

6.2.3. Solubilizers / Surfactants

6.2.4. Polyols

6.2.5. Proteins / Amino Acids

6.2.6. Other Excipient

Chapter 7. Market Segmentation 3: By Excipient Estimates & Trend Analysis

7.1. By Scale of Operation & Market Share, 2020& 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Scale of Operation:

7.2.1. Preclinical

7.2.2. Clinical

7.2.3. Commercial

Chapter 8. Biopharmaceutical Excipient Manufacturing Market Segmentation 5: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) estimates and forecasts By Biologics Types, 2019-2030

8.1.2. North America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) estimates and forecasts By Excipient, 2019-2030

8.1.3. North America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2019-2030

8.1.4. North America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

8.2. Europe

8.2.1. Europe Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Biologics Types, 2019-2030

8.2.2. Europe Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Excipient, 2019-2030

8.2.3. Europe Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

8.2.4. Europe Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) by country, 2019-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Biologics Types, 2019-2030

8.3.2. Asia Pacific Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Excipient, 2019-2030

8.3.3. Asia Pacific Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

8.3.4. Asia Pacific Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) by country, 2019-2030

8.4. Latin America

8.4.1. Latin America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Biologics Types, (US$ Million) 2019-2030

8.4.2. Latin America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Excipient, (US$ Million) 2019-2030

8.4.3. Latin America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

8.4.4. Latin America Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) by country, 2019-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Biologics Types, (US$ Million) 2019-2030

8.5.2. Middle East & Africa Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Excipient, (US$ Million) 2019-2030

8.5.3. Middle East & Africa Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

8.5.4. Middle East & Africa Biopharmaceutical Excipient Manufacturing Market revenue (US$ Million) by country, 2019-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. ABITEC

9.2.2. Avantor

9.2.3. BASF Pharma

9.2.4. Corden Pharma

9.2.5. DFE Pharma

9.2.6. Evonik

9.2.7. Kirsch Pharma

9.2.8. Merck KGaA

9.2.9. Pfanstiehl

9.2.10. Roquette

9.2.11. Spectrum Chemical Manufacturing

9.2.12. SPI Pharma

9.2.13. JRS Pharma LP

9.2.14. A&C

9.2.15. Sigachi Industries Pvt. Ltd.

9.2.16. Wacker Chemie AG

9.2.17. Other Prominent Players

Global Biopharmaceutical Excipient Manufacturing Market, by Type of Biologics, 2019-2030 (Value US$ Mn)

  • Antibodies
  • Vaccines
  • Cell Therapies
  • Other Biologics

Global Biopharmaceutical Excipient Manufacturing Market, by Type of Excipient, 2019-2030 (Value US$ Mn)

  • Carbohydrates
  • Polymers
  • Solubilizers / Surfactants
  • Polyols
  • Proteins / Amino Acids
  • Others

Global Biopharmaceutical Excipient Manufacturing Market, by By Scale of Operation, 2019-2030 (Value US$ Mn)

  • Preclinical
  • Clinical
  • Commercial

Global Biopharmaceutical Excipient Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Biopharmaceutical Excipient Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Biopharmaceutical Excipient Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Biopharmaceutical Excipient Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Biopharmaceutical Excipient Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Biopharmaceutical Excipient Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients